Complication of Diabetes Type I explained
Advertisement
An Indian origin has shed light into the development of the complications in type 1 diabetes.
Senior author Rohit Kulkarni, M.D., Ph.D., at Joslin Diabetes Center and Associate Professor of Medicine at Harvard Medical School, said that complications were a major cause of serious diseases in type 1 diabetes, which affect the cardiovascular system, kidneys, eyes and nerves.
Even with very good glycemic control, people with type 1 diabetes could still develop complications that impact their ability to work and quality of life.
In the study, induced pluripotent stem (iPS) cells, which have the potential to differentiate into any type of cell in the body, were used to model the disease. They were derived from skin cells obtained from patients who have had type 1 diabetes for 50 years or more and are members of the Joslin 50-Year Medalist Program, and also from healthy controls.
Participants were classified according to complications status: Medalist +C for severe complications and Medalist -C for absent or mild complications.
Genetic analysis of the iPS and skin cells showed "remarkable differences in expression of genes and proteins in the Medalist +C group compared to the Medalist -C group and the controls," said Dr. Kulkarni.
The analysis revealed higher levels of a protein known as miR200 in the Medalist +C group than in the Medalist -C group and controls.
This was a very significant finding because miR200 played an important role in the DNA repair process, he added.
When the scientists reduced expression of miR200 in iPS and skin cells from the Medalist +C group, the DNA damage checkpoint pathway machinery was restored and DNA damage was reduced in the cells. This makes miR200 a promising potential target for therapeutic interventions and also a possible biomarker for early detection of the development of complications.
The findings are published in Cell Metabolism. (ANI)
Senior author Rohit Kulkarni, M.D., Ph.D., at Joslin Diabetes Center and Associate Professor of Medicine at Harvard Medical School, said that complications were a major cause of serious diseases in type 1 diabetes, which affect the cardiovascular system, kidneys, eyes and nerves.
Even with very good glycemic control, people with type 1 diabetes could still develop complications that impact their ability to work and quality of life.
In the study, induced pluripotent stem (iPS) cells, which have the potential to differentiate into any type of cell in the body, were used to model the disease. They were derived from skin cells obtained from patients who have had type 1 diabetes for 50 years or more and are members of the Joslin 50-Year Medalist Program, and also from healthy controls.
Participants were classified according to complications status: Medalist +C for severe complications and Medalist -C for absent or mild complications.
Genetic analysis of the iPS and skin cells showed "remarkable differences in expression of genes and proteins in the Medalist +C group compared to the Medalist -C group and the controls," said Dr. Kulkarni.
The analysis revealed higher levels of a protein known as miR200 in the Medalist +C group than in the Medalist -C group and controls.
This was a very significant finding because miR200 played an important role in the DNA repair process, he added.
When the scientists reduced expression of miR200 in iPS and skin cells from the Medalist +C group, the DNA damage checkpoint pathway machinery was restored and DNA damage was reduced in the cells. This makes miR200 a promising potential target for therapeutic interventions and also a possible biomarker for early detection of the development of complications.
The findings are published in Cell Metabolism. (ANI)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.